display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced hepatocellular cancer (mHCC)
mHCC - 1st line (L1)mHCC - 2nd line (L2)
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus bevacizumab IMbrave-150
nivolumab based treatment
nivolumab alone CheckMate 459
pembrolizumab based treatment KEYNOTE-394
pembrolizumab alone KEYNOTE-240
pembrolizumab plus lenvatinib LEAP 002
sintilimab based treatment
sintilimab ORIENT-32

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons